REG - Verici Dx PLC - Tutivia™ abstracts for World Transplant Congress

Verici DxAnnouncement

31/07/2025 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2551Ta&default-theme=true

RNS Number : 2551T  Verici Dx PLC  31 July 2025

 

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Tutivia™ abstracts for World Transplant Congress

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that a number of abstracts relating to Tutivia™
have been published ahead of presentation at the forthcoming World Transplant
Congress in San Francisco in August 2025 (WTC 2025), a major international
event for experts in the field of organ transplantation to share research,
discuss advancements, and address challenges in transplantation.

 

The abstracts focus on the role of biomarker testing with Tutivia™ to
support medical management in important areas of unmet need including patients
with BK nephropathy and increasing BK viremia, obese patients including those
who underwent robotic transplantation, patients with delayed graft function
(DGF) and slow graft function, and patients with previous failed transplant or
multi-organ transplant.

 

The abstracts are based on real-world evidence collected at multiple
transplant centres currently utilising Tutivia™ to support clinical care for
these complex and challenging patient populations.

 

The World Transplant Congress is organised jointly by the American Society of
Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and
The Transplantation Society (TTS). https://wtc2025.org/ (https://wtc2025.org/)

 

The abstracts are available here:

(P1.07.253) Utility of Rejection Biomarker Tutivia in Managing Kidney
Transplant Recipients at Risk of BK Nephropathy:
https://cattendee.abstractsonline.com/meeting/21176/Session/306
(https://cattendee.abstractsonline.com/meeting/21176/Session/306)

 

(P3.07.218) Tutivia Biomarker Testing Provides Accurate Results for Medical
Management in Severely Obese Kidney Transplant Patients:
https://cattendee.abstractsonline.com/meeting/21176/Session/309
(https://cattendee.abstractsonline.com/meeting/21176/Session/309)

 

(P3.07.196) Use of TUTIVIA in the Early Post-Transplant Period for Distinction
of Rejection from Quiescence Among Kidney Transplant Recipients - A Single
Center Experience
https://cattendee.abstractsonline.com/meeting/21176/Session/309
(https://cattendee.abstractsonline.com/meeting/21176/Session/309)

 

(P3.07.215) The Role of Gene Expression Profile in Predicting Acute Rejection
https://cattendee.abstractsonline.com/meeting/21176/Session/309
(https://cattendee.abstractsonline.com/meeting/21176/Session/309)

 

(P3.07.216) Comparison of Gene Expression Profiling with Histopathology and
Molecular Pathology in Detection of Acute Rejection in Kidney Transplant
Recipients https://cattendee.abstractsonline.com/meeting/21176/Session/309
(https://cattendee.abstractsonline.com/meeting/21176/Session/309)

 

About Tutivia™

The Tutivia™ test is an advancement in biomarker testing utilising RNA
expression in peripheral blood and a proprietary algorithm to report a
patient's risk score for acute rejection post-transplant. The Tutivia™ test
is commercially available and already used in 20 ordering centres. Medicare
coverage has supported the strong acceleration in adoption and test ordering
volumes.

 

Commenting, Sara Barrington, CEO of Verici Dx, said: "It is a great
validation of our test for acute rejection post-transplantation to have
clinicians at multiple transplant centres sharing how it has been used to
address important areas of unmet need.. Gaining shared clinical experience at
leading transplant centers is essential to increase the adoption of Tutivia™
and in turn ultimately scale up volumes."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser and Joint Broker)                   Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Jessica Cave

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Paul McManus                 Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURUVRVOUBOAR